Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

@article{Ference2016VariationIP,
  title={Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.},
  author={Brian A. Ference and Jennifer G. Robinson and Robert D. Brook and Alberico L. Catapano and Martin John Chapman and David R. Neff and Szilard Voros and Robert P Giugliano and George Davey Smith and Sergio Fazio and Marc S. Sabatine},
  journal={The New England journal of medicine},
  year={2016},
  volume={375 22},
  pages={2144-2153}
}
BACKGROUND Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR… CONTINUE READING
84 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

Similar Papers

Loading similar papers…